Experimental combo targets genetic weakness in aggressive blood cancers
NCT ID NCT07646821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests adding ropeginterferon alfa-2b to the standard drug azacitidine for people newly diagnosed with a type of blood cancer (MDS or AML) that has a specific genetic change called a TP53 mutation. The goal is to find the safest dose of the combination and see if it can help control the disease. The trial enrolls about 30 adults and tracks side effects and disease response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ropeginterferon alfa-2b and azacitidine
- What this could lead to
- If successful, this combination could offer a new treatment option for people with a hard-to-treat form of blood cancer.
- What could go wrong
- This is an early-phase trial with only 30 participants, so the benefits are uncertain. Side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALFA-2B are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.